Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Clinical Trials for Thoracic Cancers
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Trials for Thoracic Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 30 December 2025 | Viewed by 432

Special Issue Editor

Dr. Monica Casiraghi

E-Mail Website
Guest Editor
1. Department of Thoracic Surgery, European Institute of Oncology—IEO, Milan, Italy
2. Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy
Interests: lung cancer; minimally invasive surgery; robotic surgery; mesothelioma; thymoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Thoracic cancers, including lung, thymic, and pleural malignancies, remain among the most lethal oncologic entities worldwide. In recent years, clinical research has witnessed a paradigm shift from traditional cytotoxic therapies to biomarker-driven treatments, immuno-oncology, and multimodal strategies, including advanced surgical and radiotherapy protocols. Innovations in trial design have accelerated the dynamic evolution of clinical trials, the increasing integration of artificial intelligence, and the growing emphasis on real-world evidence to complement randomized controlled trials.

This Special Issue aims to capture the breadth of ongoing progress in thoracic oncology clinical trials, focusing on innovative methodologies, translational applications, and patient-centered outcomes. We welcome original research, systematic reviews, and perspectives that address key topics such as precision medicine, novel endpoints, adaptive trial models, and the implementation of multidisciplinary treatment pathways. Contributions are especially encouraged in exploring neoadjuvant and adjuvant settings, minimally invasive interventions, and longitudinal analyses of patient-reported outcomes. By uniting diverse perspectives from thoracic surgeons, oncologists, radiologists, and data scientists, this issue aspires to foster deeper insights into how clinical research is shaping the future of thoracic cancer care.

Dr. Monica Casiraghi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • thoracic oncology
  • thymoma
  • mesothelioma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

8 pages, 215 KB  
Commentary
Evolving Resection Strategies for Non-Small Cell Lung Cancers: Translating Trial Evidence to Real-World Practice
by Akshay J. Patel, Savvas Lampridis and Andrea Bille
Cancers 2025, 17(21), 3437; https://doi.org/10.3390/cancers17213437 - 27 Oct 2025
Viewed by 266
Abstract
Background: Lobectomy has long been the gold standard for early-stage NSCLC, but recent trials challenge its universality. The Japanese JCOG0802 trial demonstrated superior overall survival with segmentectomy versus lobectomy, whereas the North American CALGB140503 trial showed non-inferiority of sublobar resection, including wedge and [...] Read more.
Background: Lobectomy has long been the gold standard for early-stage NSCLC, but recent trials challenge its universality. The Japanese JCOG0802 trial demonstrated superior overall survival with segmentectomy versus lobectomy, whereas the North American CALGB140503 trial showed non-inferiority of sublobar resection, including wedge and segmentectomy, compared with lobectomy. Methods: This commentary critically evaluates evidence from JCOG0802 and CALGB140503 in the context of wider thoracic surgical practice. We examine trial disparities, the role of real-world data, heterogeneity in surgical approach and lymph node staging, the impact of robotics on segmentectomy adoption, and the application of segmental resection in pulmonary metastasectomy. Results: The divergent trial findings reflect differences in populations, nodal staging, and surgical definitions. Worldwide, variability in sublobar practice and inconsistent nodal assessment present challenges to oncological reliability. Robotics has facilitated a rapid increase in anatomical segmentectomy but risks shifting surgical intent from necessity to feasibility. In metastasectomy, segmentectomy may improve local control but remains unproven in randomised studies. Emerging strategies such as IVLP and molecular profiling offer potential to refine patient selection and outcomes. Conclusion: Sublobar resection represents a paradigm shift in the surgical management of small NSCLC. Ensuring oncological validity in real-world practice requires rigorous nodal staging, equitable access to technology, and prospective evaluation of segmentectomy in both primary and metastatic disease. Future advances will depend on aligning surgical precision with biologically informed patient selection. Full article
(This article belongs to the Special Issue Clinical Trials for Thoracic Cancers)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop